Principal Financial Group Inc Travere Therapeutics, Inc. Transaction History

Principal Financial Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$5.26 - $8.28 $43,747 - $68,864	-8,317 Reduced 44.7%	10,288 $84,000
Q1 2024 Apr 29, 2024	BUY	$7.18 - $9.82 $1,744 - $2,386	243 Added 1.32%	18,605 $143,000
Q4 2023 Feb 07, 2024	BUY	$5.44 - $9.5 $854 - $1,491	157 Added 0.86%	18,362 $165,000
Q3 2023 Nov 02, 2023	SELL	$7.64 - $17.25 $1,352 - $3,053	-177 Reduced 0.96%	18,205 $162,000
Q2 2023 Aug 07, 2023	BUY	$15.3 - $22.61 $37,515 - $55,439	2,452 Added 15.39%	18,382 $282,000
Q1 2023 May 09, 2023	SELL	$17.82 - $22.89 $16,091 - $20,669	-903 Reduced 5.36%	15,930 $358,000
Q4 2022 Feb 09, 2023	SELL	$18.47 - $26.14 $293,931 - $415,991	-15,914 Reduced 48.6%	16,833 $353,000
Q3 2022 Nov 09, 2022	SELL	$22.91 - $28.63 $671,217 - $838,801	-29,298 Reduced 47.22%	32,747 $807,000
Q2 2022 Aug 10, 2022	BUY	$20.94 - $30.01 $1.3 Million - $1.86 Million	62,045 New	62,045 $1.5 Million
Q1 2022 May 09, 2022	SELL	$23.61 - $30.6 $171,573 - $222,370	-7,267 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$24.34 - $31.17 $101,619 - $130,134	-4,175 Reduced 36.49%	7,267 $226,000
Q3 2021 Nov 09, 2021	SELL	$12.98 - $25.03 $24,090 - $46,455	-1,856 Reduced 13.96%	11,442 $277,000
Q2 2021 Aug 10, 2021	SELL	$14.11 - $26.4 $138,489 - $259,116	-9,815 Reduced 42.47%	13,298 $194,000
Q1 2021 May 10, 2021	BUY	$23.37 - $31.77 $4,907 - $6,671	210 Added 0.92%	23,113 $577,000
Q4 2020 Feb 08, 2021	BUY	$19.17 - $27.87 $439,050 - $638,306	22,903 New	22,903 $625,000

198

84.9M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.